Kansas House Bill HB2365

Kansas 2025-2026 Regular Session

• Introduced: 2/7/25
• Refer: 2/7/25
• Report Pass: 2/18/25
• Engrossed: 2/25/25
• Refer: 2/26/25
• Report Pass: 3/17/25
• Enrolled: 4/9/26
• Passed: 4/10/26

Caption

Adding and removing certain substances in schedules I, III and IV of the uniform controlled substances act and making conforming changes to the criminal code definition of fentanyl-related controlled substances.

Impact

The enactment of HB 2365 is expected to enhance the state's ability to appropriately regulate a range of substances, particularly those that pose a risk of abuse and addiction, such as those related to fentanyl. By updating the definitions and incorporating new substances into existing schedules, the bill aims to strengthen law enforcement's capability to combat the illicit use of these substances. This is crucial as the state continues to grapple with a public health crisis linked to opioid misuse and overdose fatalities.

Summary

House Bill 2365 amends the definitions and regulations surrounding controlled substances in Kansas, with a focus on substances related to fentanyl. The bill proposes additions and removals of specific substances in Schedules I, III, and IV of the Uniform Controlled Substances Act and aligns the criminal code's definition of fentanyl-related substances with national standards. This legislative effort reflects ongoing concerns about the opioid crisis and the need to adjust control measures in response to evolving challenges associated with narcotics and their analogs.

Sentiment

The sentiment surrounding the bill is generally supportive, particularly among legislators and health advocates who view the updated regulations as necessary for public safety. Acknowledgment of the opioid crisis's severity has united many stakeholders in favor of proactive measures. However, some concerns have been raised regarding the potential for overreach in classifying new substances and its impact on medical practitioners and patients who rely on certain controlled substances for legitimate therapeutic purposes.

Contention

Notable points of contention include discussions about the classification of new substances and the implications for medical users versus those illicitly using controlled substances. Some lawmakers and groups expressed worries that stringent regulations could inadvertently limit access to necessary medications, complicating treatment for patients with legitimate health needs. The bill must balance public health priorities against the accessibility of medicinal drugs, highlighting the ongoing tension in drug policy reforms.